Alpha Sense BI

MAY 28, 2024

The venture capital landscape continues to test the discipline and diligence of investors and startups alike. Like many other asset classes, venture capital continues to be impacted by lingering macroeconomic factors affecting funding and liquidity prospects. Interest rates are high.

Capital 69

Capital Startups Biotech Due Diligence 69

Alpha Sense BI

APRIL 29, 2024

Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. Over the past few years, the technology industry has experienced dramatic highs and lows. 2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

MAY 5, 2023

Around the world, investors are favoring companies that have proven their profitability and that can demonstrate how they have successfully utilized their capital. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.

Biotech 97

Biotech Capital Banking Startups 97

Engage3

MAY 19, 2022

He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. Safaii Board Member Matthew is the founder of Arrowroot Capital. He holds B.A. He is also an entrepreneur.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

MARCH 13, 2024

According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs. Take your M&A due diligence to the next level with our Complete Guide to M&A Due Diligence.

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59